Baseline clinical characteristics of the study population
| Variable | All patients (n = 40) |
|---|---|
| Values are mean (SD) or n (%). | |
| *Medical treatment at inclusion. | |
| †Patients on only one of the three classes of antianginal drugs. | |
| ‡Patients on only sublingual glyceryl trinitrate at inclusion. | |
| ACE, angiotensin converting enzyme; CAD, coronary artery disease; CCS, Canadian Cardiovascular Society; F, female; GTN, glyceryl trinitrate; M, male; MI, myocardial infarction. | |
| Age (years) | 56 (6) |
| Sex (M/F) | 36/4 (90%) |
| Cholesterol (mmol/l) | 6 (1) |
| Triglycerides (mmol/l) | 1.9 (1.3) |
| Hypertension (yes/no) | 15/25 (37%) |
| Parental CAD (yes/no) | 19/21 (48%) |
| Smoking (yes/no) | 23/17 (57%) |
| CCS anginal class | |
| 1 | 16 (40%) |
| 2 | 19 (48%) |
| 3 | 5 (12%) |
| Diseased coronary arteries | |
| 1 | 2 (6%) |
| 2 | 17 (42%) |
| 3 | 21 (52%) |
| Previous MI (yes/no) | 21/19 (53%) |
| Drugs* | |
| β Blockers | 21/40 (53%) |
| Calcium channel blockers | 21/40 (53%) |
| Long acting nitrates | 10/40 (25%) |
| Lipid lowering | 6/40 (15%) |
| Statins | 3/40 (8%) |
| Fibrates | 3/40 (8%) |
| Antiplatelets | 14/40 (35%) |
| Diuretics | 6/40 (15%) |
| ACE inhibitors | 5/40 (13%) |
| Monotherapy† | 19/40 (48%) |
| GTN only‡ | 7/40 (18%) |